- Home
- NOTE vs VIGL Comparison
NOTE vs VIGL Comparison
Compare NOTE & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- VIGL
- Stock Information
- Founded
- NOTE 2013
- VIGL 2020
- Country
- NOTE United States
- VIGL United States
- Employees
- NOTE N/A
- VIGL N/A
- Industry
- NOTE EDP Services
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NOTE Technology
- VIGL Health Care
- Exchange
- NOTE Nasdaq
- VIGL Nasdaq
- Market Cap
- NOTE 132.5M
- VIGL 141.5M
- IPO Year
- NOTE N/A
- VIGL 2022
- Fundamental
- Price
- NOTE $0.80
- VIGL $3.19
- Analyst Decision
- NOTE Strong Buy
- VIGL Buy
- Analyst Count
- NOTE 7
- VIGL 5
- Target Price
- NOTE $3.30
- VIGL $16.80
- AVG Volume (30 Days)
- NOTE 579.3K
- VIGL 54.2K
- Earning Date
- NOTE 11-12-2024
- VIGL 11-07-2024
- Dividend Yield
- NOTE N/A
- VIGL N/A
- EPS Growth
- NOTE N/A
- VIGL N/A
- EPS
- NOTE N/A
- VIGL N/A
- Revenue
- NOTE $125,062,000.00
- VIGL N/A
- Revenue This Year
- NOTE N/A
- VIGL N/A
- Revenue Next Year
- NOTE $7.25
- VIGL N/A
- P/E Ratio
- NOTE N/A
- VIGL N/A
- Revenue Growth
- NOTE N/A
- VIGL N/A
- 52 Week Low
- NOTE $0.74
- VIGL $2.47
- 52 Week High
- NOTE $2.27
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- NOTE 28.39
- VIGL 34.61
- Support Level
- NOTE $0.77
- VIGL $3.52
- Resistance Level
- NOTE $0.98
- VIGL $3.75
- Average True Range (ATR)
- NOTE 0.09
- VIGL 0.20
- MACD
- NOTE -0.01
- VIGL -0.08
- Stochastic Oscillator
- NOTE 17.29
- VIGL 12.56
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of global policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With expert analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.